King C. Lee
Keine laufenden Positionen mehr
Profil
King C.
Lee worked as a Director of Regulatory Affairs at Vion Pharmaceuticals, Inc. from 1996 to 2001, a Manager of Regulatory Affairs & Clinical Affairs at IBEX Technologies, Inc. from 1993 to 1996, a Vice President of Regulatory Affairs at Acorda Therapeutics, Inc., and a Research Supervisor at Wyeth-Ayerst Research in 1985-1986.
He also worked as a Faculty Member at Eastern Kentucky University.
Dr. Lee earned a doctorate degree from the University of Kentucky in 1983.
Ehemalige bekannte Positionen von King C. Lee
| Unternehmen | Position | Ende |
|---|---|---|
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | General Counsel | 01.01.2001 |
| IBEX TECHNOLOGIES | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1996 |
| Wyeth-Ayerst Research | Corporate Officer/Principal | 01.01.1986 |
| Eastern Kentucky University | Corporate Officer/Principal | - |
| ACORDA THERAPEUTICS, INC. | General Counsel | - |
Ausbildung von King C. Lee
| University of Kentucky | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ACORDA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
IBEX Technologies, Inc.
 IBEX Technologies, Inc. Medical SpecialtiesHealth Technology IBEX Technologies, Inc. manufactures and markets enzymes for biomedical use. The firm also specializes in the custom aliquoting, filling, and lyophilization of enzymes in diagnostic disposables for medical devices. Its products include glycobiology enzymes from flavobacterium heparinum, collagen assays, collagen antibodies, and diamine oxidase liquid. The company was founded by Robert A. Heft on April 10, 1972 and is headquartered in Montréal, Canada. | Health Technology |
| Wyeth-Ayerst Research |
